{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:07:48Z","timestamp":1793833668828,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02434-8","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:12:13Z","timestamp":1781946733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-2782","authenticated-orcid":false,"given":"Simona","family":"Guerzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-5039","authenticated-orcid":false,"given":"Lanfranco","family":"Pellesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Giannessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8572-3421","authenticated-orcid":false,"given":"Flavia","family":"Lo Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Degli Esposti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"1","key":"2434_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s10194-024-01889-x","volume":"25","author":"A Raggi","year":"2024","unstructured":"Raggi A, Leonardi M, Arruda M, Caponnetto V, Castaldo M, Coppola G et al (2024) Hallmarks of primary headache: part 1 - migraine. J Headache Pain 25(1):189. https:\/\/doi.org\/10.1186\/s10194-024-01889-x","journal-title":"J Headache Pain"},{"issue":"1","key":"2434_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s10194-025-02049-5","volume":"26","author":"YC Liu","year":"2025","unstructured":"Liu YC, Liu YH, Pan HF, Wang W (2025) Unveiling new insights into migraine risk stratification using machine learning models of adjustable risk factors. J Headache Pain 26(1):103. https:\/\/doi.org\/10.1186\/s10194-025-02049-5","journal-title":"J Headache Pain"},{"issue":"2","key":"2434_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","volume":"19","author":"TJ Steiner","year":"2023","unstructured":"Steiner TJ, Stovner LJ (2023) Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol 19(2):109\u2013117. https:\/\/doi.org\/10.1038\/s41582-022-00763-1","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"2434_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14488","volume":"63","author":"IE Verhagen","year":"2023","unstructured":"Verhagen IE, Van Der Arend BWH, Van Casteren DS, Le Cessie S, MaassenVanDenBrink A, Terwindt GM (2023) Sex differences in migraine attack characteristics: A longitudinal E-diary study. Headache 63(3):333\u2013341. https:\/\/doi.org\/10.1111\/head.14488","journal-title":"Headache"},{"issue":"1","key":"2434_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-024-01798-z","volume":"25","author":"J Cen","year":"2024","unstructured":"Cen J, Wang Q, Cheng L, Gao Q, Wang H, Sun F (2024) Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the Global Burden of Disease Study 2021. J Headache Pain 25(1):96. https:\/\/doi.org\/10.1186\/s10194-024-01798-z","journal-title":"J Headache Pain"},{"issue":"4","key":"2434_CR6","doi-asserted-by":"publisher","first-page":"333102424130538","DOI":"10.1177\/03331024241305381","volume":"45","author":"R Ornello","year":"2025","unstructured":"Ornello R, Caponnetto V, Ahmed F, Al-Khazali HM, Ambrosini A, Ashina S et al (2025) Evidence-based guidelines for the pharmacological treatment of migraine. Cephalalgia 45(4):3331024241305381. https:\/\/doi.org\/10.1177\/03331024241305381","journal-title":"Cephalalgia"},{"issue":"8","key":"2434_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17(8):501\u2013514. https:\/\/doi.org\/10.1038\/s41582-021-00509-5","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"2434_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17581869.2025.2494494","volume":"15","author":"L Pellesi","year":"2025","unstructured":"Pellesi L, Jedie B, Barhum F, Al-Abdullah S, Martelletti P, Xiao Z (2025) Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. Pain Manag 15(5):279\u2013284. https:\/\/doi.org\/10.1080\/17581869.2025.2494494","journal-title":"Pain Manag"},{"issue":"1","key":"2434_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s10194-026-02395-y","volume":"27","author":"D Scuteri","year":"2026","unstructured":"Scuteri D, Kodounis M, Katsuki M, Bezgal B, Bednarczyk N, Alevetsovitis SK et al (2026) Pharmacological mechanisms underlying neurovascular alterations related to resistant and refractory migraine: CGRP pathways and beyond. J Headache Pain 27(1):151. https:\/\/doi.org\/10.1186\/s10194-026-02395-y","journal-title":"J Headache Pain"},{"issue":"3","key":"2434_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1474-4422(25)00477-6","volume":"25","author":"D Martinelli","year":"2026","unstructured":"Martinelli D, De Icco R, Al-Khazali HM, Ashina S, Diener HC, Dodd-Glover F et al (2026) Advances in migraine prevention. Lancet Neurol 25(3):279\u2013293. https:\/\/doi.org\/10.1016\/S1474-4422(25)00477-6","journal-title":"Lancet Neurol"},{"issue":"2","key":"2434_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/14728214.2023.2207819","volume":"28","author":"M Silvestro","year":"2023","unstructured":"Silvestro M, Orologio I, Siciliano M, Trojsi F, Tessitore A, Tedeschi G et al (2023) Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials. Expert Opin Emerg Drugs 28(2):79\u201396. https:\/\/doi.org\/10.1080\/14728214.2023.2207819","journal-title":"Expert Opin Emerg Drugs"},{"issue":"7","key":"2434_CR12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/17460441.2024.2365379","volume":"19","author":"C Baraldi","year":"2024","unstructured":"Baraldi C, Beier D, Martelletti P, Pellesi L (2024) The preclinical discovery and development of atogepant for migraine prophylaxis. Expert Opin Drug Discov 19(7):783\u2013788. https:\/\/doi.org\/10.1080\/17460441.2024.2365379","journal-title":"Expert Opin Drug Discov"},{"key":"2434_CR13","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"2434_CR14","doi-asserted-by":"publisher","unstructured":"Russo A, Silvestro M, Finkelstein I, Seabi D, Ahlden A, Aamodt AH et al (2025) Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: Six-month real-world evidence. Cephalalgia. 2025;45(8):03331024251370608. https:\/\/doi.org\/10.1177\/03331024251370608","DOI":"10.1177\/03331024251370608"},{"issue":"1","key":"2434_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-025-02068-2","volume":"26","author":"P Barbanti","year":"2025","unstructured":"Barbanti P, Egeo G, Pistoia F, Aurilia C, Scatena P, Rinalduzzi S et al (2025) GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures. J Headache Pain 26(1):122. https:\/\/doi.org\/10.1186\/s10194-025-02068-2","journal-title":"J Headache Pain"},{"issue":"4","key":"2434_CR16","doi-asserted-by":"publisher","first-page":"033310242513359","DOI":"10.1177\/03331024251335927","volume":"45","author":"F Vernieri","year":"2025","unstructured":"Vernieri F, Iannone LF, Lo Castro F, Sebastianelli G, De Santis F, Corrado M et al (2025) Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study). Cephalalgia 45(4):03331024251335927. https:\/\/doi.org\/10.1177\/03331024251335927","journal-title":"Cephalalgia"},{"issue":"1","key":"2434_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s10194-025-02086-0","volume":"26","author":"M Lanteri-Minet","year":"2025","unstructured":"Lanteri-Minet M, Casarotto C, Bretin O, Collin C, Gugenheim M, Raclot V et al (2025) Prevalence, characteristics and management of migraine patients with triptan failure in primary care: the EMR France-Mig study. J Headache Pain 26(1):153. https:\/\/doi.org\/10.1186\/s10194-025-02086-0","journal-title":"J Headache Pain"},{"issue":"4","key":"2434_CR18","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3390\/jcm15041437","volume":"15","author":"Y Barer","year":"2026","unstructured":"Barer Y, Hoshen M, Gazit S, Sharman Moser S, Tirosh M, Davivdovici D et al (2026) Triptan Use and Potential Undertreatment in Migraine: A Retrospective Cohort Study. J Clin Med 15(4):1437. https:\/\/doi.org\/10.3390\/jcm15041437","journal-title":"J Clin Med"},{"issue":"6","key":"2434_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.nrleng.2025.06.002","volume":"40","author":"J Fern\u00e1ndez-Ferro","year":"2025","unstructured":"Fern\u00e1ndez-Ferro J, Ord\u00e1s-Bandera C, Rejas-Guti\u00e9rrez J, Ferro-Rey B, G\u00f3mez-Lus S, L\u00e1inez Andr\u00e9s JM (2025) The economic burden of migraine: a nationwide cost-of-illness approach from the year 2020 European Health Survey in Spain. Neurol Engl Ed 40(6):533\u2013547. https:\/\/doi.org\/10.1016\/j.nrleng.2025.06.002","journal-title":"Neurol Engl Ed"},{"issue":"1","key":"2434_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13561-023-00459-2","volume":"13","author":"A Eltrafi","year":"2023","unstructured":"Eltrafi A, Shrestha S, Ahmed A, Mistry H, Paudyal V, Khanal S (2023) Economic burden of chronic migraine in OECD countries: a systematic review. Health Econ Rev 13(1):43. https:\/\/doi.org\/10.1186\/s13561-023-00459-2","journal-title":"Health Econ Rev"},{"issue":"1","key":"2434_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/13696998.2021.1925557","volume":"24","author":"P Martelletti","year":"2021","unstructured":"Martelletti P, Schwedt TJ, Vo P, Ritrovato D, Reilly MC, Naclerio M et al (2021) Healthcare resource use and indirect costs associated with migraine in Italy: results from the My Migraine Voice survey. J Med Econ 24(1):717\u2013726. https:\/\/doi.org\/10.1080\/13696998.2021.1925557","journal-title":"J Med Econ"},{"issue":"1","key":"2434_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-024-01755-w","volume":"25","author":"H Gosalia","year":"2024","unstructured":"Gosalia H, Moreno-Ajona D, Goadsby PJ (2024) Medication-overuse headache: a narrative review. J Headache Pain 25(1):89. https:\/\/doi.org\/10.1186\/s10194-024-01755-w","journal-title":"J Headache Pain"},{"issue":"1","key":"2434_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/14737175.2025.2596783","volume":"26","author":"L Pellesi","year":"2026","unstructured":"Pellesi L, Lo Castro F, Boccalini A, Allamprese R, Guerzoni S (2026) Medication-overuse headache: can anti-CGRP monoclonal antibodies replace withdrawal? Expert Rev Neurother 26(1):67\u201374. https:\/\/doi.org\/10.1080\/14737175.2025.2596783","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"2434_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s10194-025-02112-1","volume":"26","author":"S Saha","year":"2025","unstructured":"Saha S, Chowdhury D, Wadhwa M, Sarkar R, Raval D, Patel I et al (2025) Impact of migraine on productivity and efficiency among adult population in India: a scoping review. J Headache Pain 26(1):180. https:\/\/doi.org\/10.1186\/s10194-025-02112-1","journal-title":"J Headache Pain"},{"key":"2434_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/cjn.2024.337","volume":"4","author":"H Naik","year":"2024","unstructured":"Naik H, Tam ACT, Trenaman L, Lynd L, Zhang W (2024) Productivity Loss Associated with Disability from Migraine: A Canada-Wide Cross-Sectional Study. Can J Neurol Sci Nov 4:1\u20138. https:\/\/doi.org\/10.1017\/cjn.2024.337","journal-title":"Can J Neurol Sci Nov"},{"issue":"1","key":"2434_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s10194-022-01413-z","volume":"23","author":"LJ Krasenbaum","year":"2022","unstructured":"Krasenbaum LJ, Pedarla VL, Thompson SF, Tangirala K, Cohen JM, Driessen MT (2022) A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. J Headache Pain 23(1):54. https:\/\/doi.org\/10.1186\/s10194-022-01413-z","journal-title":"J Headache Pain"},{"issue":"1","key":"2434_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s10194-025-02028-w","volume":"26","author":"L Pellesi","year":"2025","unstructured":"Pellesi L, Do TP, Ernst MT, Hallas J, Potteg\u00e5rd A (2025) Adoption of rimegepant in Denmark: a register-based study on uptake, prescribing patterns and initiator characteristics. J Headache Pain 26(1):83. https:\/\/doi.org\/10.1186\/s10194-025-02028-w","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02434-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02434-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02434-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:09:29Z","timestamp":1782284969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02434-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2434"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02434-8","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Area Vasta Emilia Nord Ethics Committee of Modena (protocol number: 125\/2020\/OSS\/AOUMO) and conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Simona Guerzoni has received speaker honoraria and consulting fees from Teva, Eli Lilly\/Organon, Abbvie, Pfizer, Organon and Lundbeck. Lanfranco Pellesi has received consulting fees from Eli Lilly and serves as an editorial board member; no involvement occurred in any review or editorial decision-making process related to this paper. Flavia Lo Castro has received speaker honoraria from Organon and AbbVie. The other authors report no competing interests in relation to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}